Literature DB >> 7921411

Analysis of adhesion molecules in Ki-1 anaplastic large-cell lymphoma.

M Akamatsu1, M Takeshita, K Ohshima, M Kikuchi, J Suzumiya.   

Abstract

We analysed the expression of adhesion molecules on lymphoma cells in 13 patients with Ki-1 (CD30)-positive anaplastic large-cell lymphoma (Ki-1 ALCL; lymph nodes in 6, extranodal tumours in 6, and both lymph nodes and bone in 1). Very late activation antigen (VLA)-alpha 4 (CD49d) and Hermes lymph node homing receptor (CD44) were constantly expressed in all specimens, and intercellular adhesion molecule-1 (ICAM-1; CD54) was frequently expressed in 10 of the 14 specimens. The expressions of lymphocyte function-associated antigen-1 alpha (LFA-1 alpha; CD11a) and VLA-alpha 5 (CD49e) occurred in 5 of 14 and 4 of 14 specimens, respectively. The expression of VLA-alpha 2 (CD49b), endothelial leukocyte adhesion molecule-1, neural cell adhesion molecule (CD56) and E cadherin were always lacking. VLA-alpha 6 (CD49f) was absent in all but one specimen. The expression of VLA-alpha 5 on Ki-1 ALCL was high in subcutis-cutis but absent in lymph nodes. Furthermore, in one case, LFA-1 alpha was detected in the primary lymph node, but was absent in a metastatic bone lesion. These results suggest that the expression of ICAM-1 is partially responsible for aleukemic behaviour in Ki-1 ALCL and, moreover, that the Ki-1 ALCL cells modify their expression of adhesion molecules at each of the involved organs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921411     DOI: 10.1007/bf00193946

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Anti-human T-cell lymphotrophic virus type I antibody-positive adult T-cell leukemia/lymphoma with no monoclonal proviral DNA. A clinicopathologic and immunologic study.

Authors:  T Yoshida; M Kikuchi; K Ooshima; M Takeshita; N Kimura; M Kozuru; H Satoh
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

Review 2.  Integrins.

Authors:  E Ruoslahti
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

Review 3.  VLA proteins in the integrin family: structures, functions, and their role on leukocytes.

Authors:  M E Hemler
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

4.  Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia.

Authors:  G Inghirami; R Wieczorek; B Y Zhu; R Silber; R Dalla-Favera; D M Knowles
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

5.  Regulation of expression of a human intercellular adhesion molecule (ICAM-1) during lymphohematopoietic differentiation.

Authors:  A W Boyd; S M Dunn; J V Fecondo; J G Culvenor; U Dührsen; G F Burns; S O Wawryk
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

6.  Organ preference of metastasis. The role of organ-specifically modulated endothelial cells.

Authors:  B U Pauli; C L Lee
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

7.  Adhesion receptor profile of thymic B-cell lymphoma.

Authors:  A Eichelmann; K Koretz; G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 8.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

9.  Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54).

Authors:  E Horst; C J Meijer; T Radaszkiewicz; G J Ossekoppele; J H Van Krieken; S T Pals
Journal:  Leukemia       Date:  1990-08       Impact factor: 11.528

10.  Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.

Authors:  E A Wayner; A Garcia-Pardo; M J Humphries; J A McDonald; W G Carter
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.